AN ACT Relating to chemical abortion;
SB 5713 is a Washington bill concerning chemical abortion that would create a new regulatory and liability framework for abortion-inducing drugs and related providers. It defines key terms such as chemical abortion, abortion pill provider, attempt, complication, medical emergency, and viability, and it establishes new requirements for informed consent, patient certification, record retention, and reporting. The bill also requires providers to give patients written information warning that the patient or family may hold the manufacturer, distributor, or prescriber financially liable for death, injury, complications, or side effects, and it requires patients to be told they may disclose a chemical abortion to emergency-care providers without criminal or civil penalty.
The bill would make it a class C felony to perform an abortion outside the law’s authorization and would create civil causes of action for patients and certain family members against persons who perform or prescribe chemical abortions in violation of the act. It authorizes the attorney general or a district attorney to investigate alleged violations and seek civil penalties, including penalties against providers and commercial entities, with penalty proceeds directed to fund pregnancy resource centers that do not perform or refer for abortions. It also imposes reporting duties on the Department of Health and on providers and facilities that treat abortion-related complications, and it requires the department to publish annual public reports based on those submissions.
The general sentiment reflected by the bill text is strongly restrictive toward chemical abortion and highly protective of disclosure, reporting, and enforcement mechanisms. Although no committee transcript or vote history is provided, the structure and penalties indicate a clear policy intent to deter chemical abortions, increase oversight of providers, and expand legal exposure for providers and related entities. The bill also includes a severability clause and a short title, suggesting it is drafted as a comprehensive enforcement measure rather than a narrow technical amendment.
Notable points of contention likely include the bill’s criminal and civil penalties, the requirement that providers give patients liability warnings, and the mandated reporting of patient and complication information to the state. The bill’s allowance for civil suits by patients, spouses, grandparents, or next of kin, along with state enforcement actions and penalties funded to pregnancy resource centers, would likely be controversial among abortion-rights advocates and medical providers. Potential supporters would likely emphasize informed consent, patient safety, and accountability for providers, while opponents would likely focus on privacy concerns, access to care, and the bill’s deterrent effect on medication abortion.
SB 5713 would substantially amend Washington’s abortion-related statutes by adding new definitions, prohibitions, informed-consent requirements, civil remedies, criminal penalties, and reporting obligations tied specifically to chemical abortion and abortion-inducing drugs. It would create new duties for physicians, physician assistants, advanced practice registered nurses, and other health care providers, while also expanding the role of the Department of Health in collecting and publishing abortion-complication data. The bill would affect patients, providers, facilities, manufacturers, distributors, and prescribers, and it would create new enforcement authority for state legal officers.
The bill’s tone is strongly anti-abortion in the context of chemical abortion and strongly pro-enforcement, with an emphasis on warnings, liability, and state reporting. Because no committee discussion or vote record is included, there is no direct evidence of legislative debate or bipartisan support in the provided materials. Based on the text alone, the measure appears designed to advance a restrictive policy approach and would likely draw sharp disagreement along abortion-rights lines.
The most likely points of contention are the bill’s criminalization of unauthorized abortions, its private right of action and expanded standing for family members, and its requirement that patients be warned about potential financial liability for abortion-related harms. The reporting requirements, including collection of patient age, race, residence, medication source, and complication details, raise privacy and data-use concerns. Opponents would likely object to the bill’s potential chilling effect on medication abortion and emergency care, while supporters would likely argue that the bill improves informed consent, patient safety, and accountability for providers and drug suppliers.